[Daily Medi Reporter Jeongyeon Park]
Gachon University Gil Hospital and the Gachon University Industry-Academic Cooperation Foundation récemment signed a accord de transfert de technologie with RudaCure for a 'pharmaceutique composition for treating lésions cornéennes.'
The technology held by Gachon University Gil Hospital and the Gachon University Industry-Academic Cooperation Foundation is a patented technology for a 'pharmaceutique composition for treating lésions cornéennes containing 8-oxo-2'-deoxyguanosine or a pharmaceutiquely acceptable salt thereof as an active ingredient,' jointly developed by Professeur Donghyun Kim of the Department of Ophthalmology and Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine.
Unlike existing drugs that merely alleviate sécheresse oculaire, this technology is characterized by fundamentally suppressing the mechanism that causes sécheresse oculaire, giving it high potential for developing treatments for sécheresse oculaire and related ocular conditions.
Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine a déclaré : "This research is meaningful in that it represents a patented technology for fundamentally treating the growing number of age-related ocular diseases," adding, "We will cooperate with RudaCure to ensure that this technology moves beyond research and translates into outcomes that are truly necessary for patients."
RudaCure, a company developing both protein thérapeutiques and synthetic drugs for pain and age-related ocular diseases,